New indication for J&J's Remicade approved by FDA

05/19/2005 | Bloomberg Businessweek

The FDA approved Johnson & Johnson's Remicade for reduction of psoriatic arthritis, putting the product in competition with Amgen's blockbuster arthritis drug Enbrel. Both drugs already are approved for treatment of other inflammatory diseases such as rheumatoid arthritis and ankylosing spondylitis.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
Actuary
Meridian Health Plan
Detroit, MI
Chief Financial Officer
B. E. Smith
Miramar, FL